Biotech Co.** (Country) | Pharma Co. (Symbol/Country) | Type/Product Area | Amount | Terms/Details (Month) |
Allelix Neuroscience Inc. (subsidiary of Allelix Biopharmaceuticals Inc.;Canada) | Janssen Pharmaceutica NV (Belgium; unit of Johnson & Johnson; NYSE:JNJ) | Research collaboration; use of Allelix's glycine re-uptake inhibitor technology (targets GlyT-1 gene) to develop drugs for neuropsychiatric disorders, especially schizophrenia | $6M (equity; % ND) | Allelix gets US$4M up front, US$2M as cash license fee, research funds for 2 years, milestones and royalties; Johnson & Johnson Development Corp. will buy US$2M in convertible preferred stock (already owns 1.6% stake prior to this); Janssen has option to extend agreement; Janssen has worldwide marketing rights but Allelix gets option to co-promote in Canada (prices converted at a rate of C$1.55/US$1) (11/98) |
Angiotech Pharmaceuticals Inc. (Canada) | C.R. Bard Inc. (NYSE:BCR) | License and development agreement; use of Angiotech's paclitaxel and related compounds for perivascular treatment of restenosis associated with vascular surgery | $19.4M | Angiotech gets total of US$19.4M in up-front license fees and milestones, plus royalties; both companies will fund product development; Bard and its subsidiary IMPRA Inc. get exclusive worldwide license (prices converted at rate of C$1.55/US$1) (12/98) |
Antigenics LLC* | Sigma-Tau (Italy) | Collaboration; clinical trials on Antigenics' heat shock protein vaccines (HSPPC-96 is in Phase II trial for melanoma and colorectal cancer) | ND | Sigma-Tau will conduct clinical trials in Italy and will provide logistical and financial support; further details ND (10/98) |
ArQule Inc. | The R.W. Johnson | Collaboration; use of | ND | 4-year agreement; Johnson gets sub- |
Pharmaceutical | ArQule's Mapping Array | scription to Mapping Array program for | ||
Research Institute | program (small-molecule | which it pays annual fees; ArQule will | ||
(unit of Johnson | compound libraries) to | deliver 1.1M compounds over 4 years; | ||
& Johnson; | discover lead compounds | Johnson gets non-exclusive license to | ||
NYSE:JNJ) | in various therapeutic areas | ArQule's process of designing and | ||
manufacturing arrays; ArQule gets mile- | ||||
stones and royalties (12/98) | ||||
Axys Pharma- | Rhone-Poulenc | Research collaboration | $80M | 2-year collaboration, which Rhone-Pou- |
ceuticals Inc. | Rorer Inc. (sub- | on small molecule thera- | lenc can extend for additional 2 years; | |
sidiary of Rhone- | peutics that inhibit | Rhone-Poulenc gets exclusive rights to | ||
Poulenc SA; | cathepsin S (cysteine | products for treating respiratory dis- | ||
NYSE:RP; France) | protease associated with | eases, atherosclerosis and rheumatoid | ||
inflammation), initally | arthritis; Axys gets $80M in research | |||
for treating asthma | funds, license fees and milestones, as | |||
well as royalties (12/98) | ||||
BioChem Pharma | SmithKline | Rsearch collaboration on | ND | Initial period of joint development to be |
Inc. (Canada) | Biologicals SA | BioChem's influenza | funded by both parties; companies will | |
(Belgium; unit of | vaccine technologies, | collaborate to market products in U.S.; | ||
SmithKline | including cell-derived | SmithKline gets exclusive license else- | ||
Beecham plc; | injectable and nasal | where; SmithKline will manufacture for | ||
NYSE:SBH; U.K.) | delivery technologies | markets worldwide except Canada, | ||
(including Light-Biovector | where BioChem retains all exclusive | |||
system licensed from | rights; BioChem gets up-front and mile- | |||
Biovector Therapeutics SA) | stone payments (12/98) | |||
Cambridge | Bayer Corp. (unit | Research collaboration on | $26M | Bayer responsible for all development |
NeuroScience Inc. | of Bayer AG; | Cambridge Neuro's recom- | costs, including reimbursement of | |
Germany) | binant glial growth factor | Cambridge Neuro's research costs; | ||
2 (stimulates re-myelination | Bayer gets exclusive worldwide manu- | |||
of nerve cells) for treating | facturing and marketing rights; Cam- | |||
neurodegenerative diseases, | bridge Neuro gets $26M in cash and | |||
including multiple sclerosis | milestones, as well as royalties; compa- | |||
nies have already worked together (for | ||||
1 year) to develop manufacturing pro- | ||||
cess for product (12/98) | ||||
Cell Genesys Inc. | Japan Tobacco | Collaboration on selected | $152.7M | Companies will share equally both pro- |
Inc. (Japan) | products from Cell Gene- | duct development costs and profits; Cell | ||
sys' GVAX cancer vaccine | Genesys gets marketing rights in North | |||
program (gene therapy, both | America; Japan Tobacco gets rights in | |||
autologous and allogeneic | Japan, Taiwan and Korea; companies | |||
approaches to treating | will share equally Europe and rest of | |||
tumor cells ex vivo with | world; Cell Genesys gets $12.7M on | |||
granulocyte macrophage- | signing, $2.5M at 1-year anniversary, | |||
colony stimulating factor to | $27.5M in R & D funds over 1st 3 years | |||
stimulate immune response; | and $80M in milestones through regula- | |||
currently in Phase I/II trials | tory approvals of 2 products; Cell Gene- | |||
for prostate cancer, lung | sys also gets $30M loan to cover its | |||
cancer and melanoma); | costs for Phase III trials; companies will | |||
collaboration's initial focus | also support ongoing clinical trial in | |||
on 2 targets (prostate cancer | Japan of GVAX for kidney cancer; if | |||
and an unidentified target) | parties agree to proceed with develop- | |||
ment of this product, Cell Genesys gets | ||||
reimbursed for R & D plus other non- | ||||
specified payments; of $152.7M total | ||||
funds, Cell Genesys gets $45M during | ||||
1st 2 years (12/98) | ||||
Chiroscience | Penwest Pharma- | Collaboration to develop | ND | 3-year agreement; both companies will |
Group plc (U.K.) | ceuticals Co. | controlled-release oral | fund R & D and will share profits | |
(NASDAQ:PPCO) | formulations of drug | equally; Chiroscience will perform | ||
isomers | chemical, preclinical and clinical | |||
development; Penwest will perform | ||||
pharmacokinetic analysis and product | ||||
formulation (12/98) | ||||
Cima Labs Inc. | Organon (unit of | Development and license | ND | Cima will develop product in exchange |
Akzo Nobel NV; | option agreement; develop- | for option and development fees; Org- | ||
the Netherlands) | ment of OraSolv fast-dis- | anon gets license option (12/98) | ||
solve formulation of one of | ||||
Organon's prescription drugs | ||||
Cistron Biotech- | Pasteur Merieux | Collaboration and option | $32.9M | Pasteur Merieux has 3-year option to |
nology Inc. (OTC | Connaught (unit | agreement on use of | (equity; | acquire exclusive license to technology; |
Bulletin Board:CIST) | of Rhone-Poulenc | Cistron's interleukin-1 | % ND) | Pasteur Merieux will pay $0.9M over |
Group; NYSE:RP; | beta as adjuvant for thera- | 3 years to fund R & D; if it exercises | ||
France) | peutic and preventative | option, Cistron gets $31M in milestones, | ||
vaccines | plus royalties; Pasteur Merieux also | |||
paid $1M total for 1.33M shares Cistron | ||||
common stock and warrants to buy | ||||
0.67M shares at $0.25 per share (10/98) | ||||
Compugen Ltd.* | Parke-Davis | Bioinformatics collabor- | ND | 3-year agreement; details ND (11/98) |
(Israel) | (division of | ation; use of Compugen's | ||
Warner-Lambert | LEAD bioinformatics | |||
Co.; NYSE:WLA) | technology to identify | |||
drug targets based on | ||||
analysis of expressed | ||||
sequence tags and genomic | ||||
databases | ||||
Cortech Inc. (OTC | United | Product development and | ND | Cortech gets up-front license fee of |
Bulletin Board: | Therapeutics | license agreement on | $0.25M; United Therapeutics will fund | |
CRTQ) | Corp.* | Cortech's elastase inhibitor | all future product development; Cortech | |
CE-1037 for treating | gets milestones and royalties (11/98) | |||
emphysema and other | ||||
diseases | ||||
CuraGen Corp. | Glaxo Wellcome | Pharmacogenomics-based | $48M | 5-year collaboration; Curagen gets |
plc (NYSE:GLX; | collaboration; use of Cura- | $2.75M annually plus milestones and | ||
U.K.) | Gen's GeneCalling and Seq- | royalties; CuraGen will evaluate var- | ||
Calling technologies to eval- | ious compounds across Glaxo's thera- | |||
uate activity of undisclosed | peutics areas and identify gene respon- | |||
Glaxo drug candidates in pre- | ses associated with toxicity and efficacy | |||
clinical studies in animals | (11/98) | |||
to guide selection of drug | ||||
candidates for human trials | ||||
(gene expression profiling) | ||||
Cytel Corp. | Japan Tobacco | Technology agreements on | ND | Cytel gets exclusive rights to enzymes; |
Inc. and Marukin | 2 enzymes for use in | Japan Tobacco will supply technology | ||
Shoyu Co. Ltd. | Cytel's carbohydrate syn- | for making particular bacterial enzyme; | ||
(both Japan) | thesis technology | Cytel has 3-year option to evaluate and | ||
take out exclusive worldwide license; | ||||
Japan Tobacco retains right to use | ||||
enzyme for its own purposes; Cytel also | ||||
gets exclusive worldwide rights to | ||||
Marukin's enzyme and will pay Maru- | ||||
kin fees and royalties (10/98) | ||||
Dendreon Corp.* | Kirin Brewery Co. | Collaboration; develop- | ND | Kirin gets exclusive marketing rights in |
Ltd. (Japan) | ment of therapeutics based | (includes | Japan and other Asian and Oceanic | |
on Dendreon's dendritic | equity) | countries; companies will co-commer- | ||
cell technology; also, | cialize some products in Europe; Kirin | |||
research agreement to | made equity investment in Dendreon | |||
jointly develop dendritic | and will buy more equity in Dendreon's | |||
cells as products per se | IPO; Kirin has option to license den- | |||
dritic cell products; Dendreon gets | ||||
signing fee, milestones and royalties; | ||||
Dendreon gets option for exclusive | ||||
license to products developed by Kirin | ||||
based on technology, which it would | ||||
market in North America (12/98) | ||||
Diatide Inc. | Merck & Co. Inc. | License agreement on | ND | Diatide gets non-exclusive license to |
(NYSE:MRK) | Merck's technology (not | develop, manufacture and market pro- | ||
described) for use in | ducts covered by Merck's patent (12/98) | |||
Diatide's pulmonary | ||||
imaging product P748 | ||||
(currently in Phase II | ||||
trials for imaging pul- | ||||
monary embolisms) | ||||
Dura Pharma- | Eli Lilly and Co. | Collaboration; use of | ND | Dura gets up-front payment, research |
ceuticals Inc. | (NYSE:LLY) | Dura's Spiros pulmonary | funds and milestones; Dura also gets | |
drug delivery technology | manufacturing fees and royalties; Lilly | |||
for insulin products | gets worldwide marketing rights (9/98) | |||
(powder for inhalation) | ||||
Elan Corp. plc | Medi-Ject Corp. | License agreement on | ND | Medi-Ject gets exclusive license; separ- |
(Ireland) | (NASDAQ:MEDJ) | Elan's injectable drug | ately, Elan invested $1M in Medi-Ject | |
delivery technology | in exchange for preferred stock and | |||
warrants (11/98) | ||||
Endocyte Inc.* | Rhone-Poulenc | Research collaboration; | $40M | Rhone-Poulenc Rorer gets exclusive |
Rorer Inc. (sub- | use of Endocyte's vitamin- | license for use of folate receptors for | ||
sidiary of Rhone- | based vector technology | delivery of oncology gene therapies; | ||
Poulenc SA; | for systemic delivery of | it has 2-year option to expand scope of | ||
NYSE:RP; France) | gene therapies for cancer; | license to include other vitamin-receptor | ||
initially focus on use of | patents; Endocyte gets $40M in license | |||
folate (folic acid) receptors | fees, R & D funding and milestones | |||
(12/98) | ||||
EnzyMed Inc.* | Merck & Co. Inc. | Research collaboration; | ND | EnzyMed gets up-front fee, milestones |
(NYSE:MRK) | use of EnzyMed's combi- | and royalties; details ND (12/98) | ||
natorial biocatalysis tech- | ||||
nology to optimize certain | ||||
of Merck's compounds | ||||
Genetronics | Ethicon Inc. | Licensing and supply | $21M | Johnson & Johnson Development Corp. |
Biomedical Ltd. | (unit of Johnson | agreement on Genetronics' | (equity; | will buy $6M in stock at market; |
& Johnson; | electroporation for delivery | % ND) | Genetronics gets $15M up-front license | |
NYSE:JNJ) | of chemotherapeutic drugs | fee, milestones and percent of net sales; | ||
to solid tumors | Ethicon gets worldwide exclusive rights | |||
to technology; Ethicon will help develop | ||||
and test system in clinic; Ethicon will | ||||
conduct regulatory activities worldwide | ||||
except in Canada, where Genetronics | ||||
retains rights (10/98) | ||||
Genome Pharma- | Byk Gulden | Research collaboration; | $30M | 5-year collaboration; Byk Gulden will |
ceuticals Corp. AG* | (subsidiary of | use of Genome Pharma- | fund 3 specific research projects; | |
(Germany) | Altana AG; | ceuticals' functional | Genome Pharmaceuticals gets up- | |
Germany) | genomics technology to | front payment and milestones for all | ||
discover genomic targets | targets accepted by Byk Gulden; it also | |||
for controlling infections | gets success fees on commercialization; | |||
caused by Helicobacter | Genome Pharmaceuticals can use tar- | |||
pylori and Chlamydia | gets not accepted by Byk Gulden as | |||
pneumoniae | basis for other partnerships (12/98) | |||
Genome | Hoechst Marion | License agreement on | ND | Hoechst Marion gets exclusive access to |
Therapeutics Corp. | Roussel Inc. | Genome Therapeutics' | database; Genome Therapeutics gets | |
(subsidiary of | microbial sequence data- | annual subscription fees and royalties | ||
Hoechst AG; | base PathoGenome | on any small molecule products; | ||
Germany) | Genome Therapeutics retains certain | |||
rights for use of genes or gene products | ||||
(10/98) | ||||
Genset SA | Pharmacia & | Pharmacogenomics | ND | 2-year agreement; Genset gets research |
(France) | Upjohn Inc. | collaboration; use of | fees, milestones and royalties; it also | |
(NYSE:PNU; U.K.) | Genset's high resolution | gets royalties on 2nd-generation com- | ||
bi-allelic marker map to | pounds based on genes identified; | |||
identify genetic markers | financial terms ND (10/98) | |||
in patients involved in | ||||
clinical study of a Pharma- | ||||
cia & Upjohn drug (i.e., | ||||
responders and non- | ||||
responders) | ||||
Genzyme Molecular | Schering-Plough | License agreement on | $40M | This is separate agreement from 1/98 |
Oncology | Corp. (NYSE:SGP) | Genzyme Molecular's | research alliance; Genzyme Molecular | |
p53 gene therapy rights | gets $5M up-front fee and $35M in | |||
patent, development and sales mile- | ||||
stones, as well as royalties; Schering- | ||||
Plough gets worldwide license on use | ||||
of p53 gene in gene therapy products; | ||||
Genzyme Molecular retains rights in | ||||
areas outside gene therapy (diagnostics, | ||||
therapeutics) (10/98) | ||||
Hyseq Inc. | Kirin Brewery Co. | Gene discovery collabor- | $3M | Companies will co-develop and co-mar- |
Ltd. (Japan) | ation; use of Hyseq's | ket products; Hyseq gets $3M for 1st | ||
gene discovery platform | phase of collaboration; Hyseq retains | |||
to target genes involved in | rights to 100% of North American pro- | |||
cell growth regulation from | fits and will pay milestones and royal- | |||
specific cell lines of Kirin's | ties to Kirin; Kirin has rights in Asia | |||
and Oceania; companies will share | ||||
profits equally from sales in Europe and | ||||
rest of world; 2-year alliance (10/98) | ||||
Icos Corp. | Eli Lilly and Co. | Formation of joint venture | $75M | Lilly will fund 50/50 joint venture for 1st |
(NYSE:LLY) | to develop and market | 3 years, after which companies will con- | ||
phosphodiesterase type 5 | tribute equally; Icos will contribute intel- | |||
(PDE5) inhibitors as oral | lectual property and research plaform | |||
therapeutics for male and | associated with IC 351; Icos gets $75M in | |||
female sexual dysfunction | up-front payment and milestones; joint | |||
(IC 351 currently in Phase | venture will market products in North | |||
II trials for male erectile | America and Europe; Lilly will market else- | |||
dysfunction) | where and pay royalties to Icos (10/98) | |||
Igen International | Bristol-Myers | Rights to Igen's Origen | ND | Bristol-Myers will purchase Origen |
Inc. | Squibb Co. | high-throughput drug dis- | system and get a pre-launch production | |
(NYSE:BMY) | covery system (based on | model; further details ND (10/98) | ||
electrochemiluminescence) | ||||
Schering-Plough | Rights to Igen's Origen | ND | Schering-Plough will purchase Origen | |
Corp. (NYSE:SGP) | high-throughput drug dis- | system and get a pre-launch production | ||
covery system (based on | model; further details ND (11/98) | |||
electrochemiluminescence) | ||||
ImClone Systems | Merck KGaA | Collaboration on ImClone's | $90M | This is 2nd collaboration between |
Inc. | (Germany) | chimeric monoclonal | (equity; | companies; Merck gets exclusive rights |
antibody C225 (inhibits | no great- | to drug outside North America, except | ||
epidermal growth factor | er than | in Japan, where partners will co-develop; | ||
receptor) for treating | 19.9%) | ImClone retains rights in North America; | ||
various solid tumors | ImClone gets $30M in up-front fees and | |||
(about to enter Phase | early cash-based milestones, $30M in late- | |||
III trials) | stage, equity-based milestones (but not | |||
more than 19.9% total equity stake) and | ||||
$30M in credit line to build commercial | ||||
manufacturing facility; Merck will fund | ||||
clinical development outside North | ||||
America; ImClone will develop product | ||||
exclusively in North America; ImClone | ||||
gets royalties on Merck's sales (12/98) | ||||
Incyte Pharma- | Schering-Plough | Broad genomic data | ND | Schering-Plough gets access to data |
ceuticals Inc. | Corp. (NYSE:SGP) | collaboration; use of | from Incyte's custom and pre-fabricated | |
Incyte's microarray tech- | DNA microarrays; Incyte gets technol- | |||
nology and databases | ogy access and per-array fees; multi- | |||
(including LifeSeq and | year collaboration; financial terms ND | |||
LifeSeq FL) in Schering- | (10/98) | |||
Plough's research programs | ||||
Isis Pharma- | Zeneca Pharma- | Research collaboration on | $40M | 3-year collaboration; Isis will create |
ceuticals Inc. | ceuticals (unit of | antisense-based drugs for | product candidates; companies will | |
Zeneca Group | treating cancer; initial focus | jointly screen these for undisclosed | ||
plc; NYSE:ZEN; | on 2 unidentified molecular | targets; Zeneca responsible for product | ||
U.K.) | targets | development; Isis gets $40M, composed | ||
of technology access fee, annual | ||||
research funds and milestones, as well | ||||
as royalties; Zeneca gets exclusive | ||||
worldwide rights to drugs; collaboration | ||||
is extendable into additional targets in | ||||
cancer and other therapeutic areas | ||||
(12/98) | ||||
Kosan | The R.W. Johnson | Research and license | ND | Kosan gets up-front payment, multi-year |
Biosciences Inc.* | Pharmaceutical | agreement; use of Kosan's | research funding, milestones and royal- | |
Research Institute | combinatorial biosynthesis | ties; Johnson & Johnson companies | ||
and Ortho-McNeil | technology to make macro- | get worldwide rights to antibacterial | ||
Pharmaceutical | lide antibiotics (generates | products; Research Institute responsible | ||
Inc. (both Johnson | analogues of bioactive | for product development; Ortho will | ||
& Johnson com- | natural products via genetic- | market in U.S.; other Johnson & John- | ||
panies; NYSE:JNJ) | ally engineered biosynthetic | son companies will market elsewhere | ||
pathways) | (10/98) | |||
Matrix Pharma- | Hoechst Marion | License agreement on | ND | Matrix will pay Hoechst Marion license |
ceutical Inc. | Roussel Inc. | Hoechst Marion Roussel's | fee; milestones and royalties; Matrix | |
(subsidiary of | anticancer agent FMdC | gets worldwide license, except in Japan | ||
Hoechst AG; | (nucleoside analogue that | (9/98) | ||
Germany) | inhibits DNA replication | |||
and cell division; completed | ||||
Phase I trials) | ||||
Medarex Inc. | Novartis Pharma | License agreement on | $50M | Novartis licensed worldwide rights to |
AG (Switzerland) | Medarex's HuMAb-Mouse | (equity; | use technology company-wide to make | |
technology for making | % ND) | antibodies to unlimited number of | ||
fully human monoclonal | targets over 10 years; Medarex gets | |||
antibodies | technology access fees, license fees and | |||
milestones of $50M; Medarex also gets | ||||
royalties; Novartis made initial payment | ||||
of $2M (in equity), and will buy $1M | ||||
additional equity after 1 year and $3M | ||||
in equity after 5 years (11/98) | ||||
Medical Science | Glaxo Wellcome | Development and license | ND | ND (12/98) |
Systems Inc. | plc (NYSE:GLX; | agreement; use of Medical | ||
U.K.) | Science's BioFusion tech- | |||
nology to develop computer | ||||
model for new compound | ||||
screening (computer-based | ||||
simulation models of | ||||
complex biological systems) | ||||
MedImmune Inc. | Pasteur Merieux | License agreement; use of | ND | Pasteur Merieux gets exclusive world- |
Connaught (unit | MedImmune's decorin- | wide rights to technology; MedImmune | ||
of Rhone-Poulenc | binding protein technology | gets milestones and royalties; further | ||
Group; NYSE:RP; | to develop 2nd-generation | details ND (12/98) | ||
France) | vaccine for prevention of | |||
Lyme disease | ||||
Millennium Phar- | Bayer AG | Broad, genomics-based | $465M | Bayer gets access to genomics-based |
maceuticals Inc. | (Germany) | drug discovery alliance; | (14% | targets for drug development over 5 |
use of Millennium's tech- | equity) | years; Millennium can develop targets | ||
nologies in genetics, geno- | not chosen by Bayer; Millennium will | |||
mics, automation and bio- | identify and validate targets and will | |||
informatics to supply | share responsibility with Bayer for | |||
225 new drug targets to | making screening assays; Bayer respon- | |||
Bayer in areas of cardio- | sible for high-throughput screening; | |||
vascular disease, cancer, | Millennium gets total of $465M, up to | |||
osteoporosis, pain, liver | $368.4M of which is guaranteed fund- | |||
fibrosis, hematology and | ing and performance fees for identified | |||
viral infections | targets plus license fees for use of | |||
(production-oriented | Millennium's genomics technology; the | |||
approach to move compounds | remaining $96.6M is equity investment | |||
from discovery to clinic) | (4.69M shares or 14% stake); Millen- | |||
nium received $130M ($96.6M for | ||||
equity, $33.4M unfront license fee) on | ||||
11/11/98; companies will share respon- | ||||
sibility for qualifying and developing | ||||
lead compounds; Bayer gets worldwide | ||||
rights to market small molecule drugs | ||||
it chooses to develop from leads; | ||||
Millennium gets royalties; Millennium | ||||
retains rights to use information genera- | ||||
ted to develop therapeutics and diag- | ||||
nostics (9/98) | ||||
MitoKor Inc.* | Pfizer Inc. | Research collaboration; | ND | MitoKor will identify molecular targets |
(NYSE:PFE) | identification of multiple | (includes | that will be screened for drug candi- | |
molecular targets and drug | equity) | dates; companies will work together to | ||
candidates (based on mito- | identify development candidates; | |||
chondrial dysfunction) for | Pfizer will make up-front cash payment | |||
treating neurodegenerative | and buy equity in MitoKor; MitoKor | |||
diseases | also gets additional cash and equity on | |||
milestones; Pfizer will fund R & D; | ||||
specific terms ND (11/98) | ||||
Molecular Simula- | Bayer AG | Bayer joined Molecular | ND | ND (11/98) |
tions Inc. (wholly | (Germany) | Simulations' Polymer | ||
owned subsidiary of | 2000 and pharmaceutical | |||
Pharmacopeia Inc.) | development consortia | |||
(application of compu- | ||||
tational chemistry to | ||||
pharmaceutical develop- | ||||
ment and formulation) | ||||
Molecumetics Ltd. | Choongwae | License and supply agree- | ND | 2-year agreement; Choongwae will |
(subsidiary of | Pharma Corp. | ment on certain key chemi- | synthesize and deliver compounds to | |
Tredegar Indus- | (South Korea) | cal intermediates for synthe- | Molecumetics; it will also perform in | |
tries; NYSE:TG) | sis of compounds using Mo- | vitro and in vivo testing of oral tryptase | ||
lecumetics' SMART library | inhibitors that will be jointly developed; | |||
technology; also, research | Choongwae gets rights to inhibitors in | |||
collaboration on oral tryptase | certain Asian countries; Molecumetics | |||
inhibitors for treating asthma, | retains rights in all other countries | |||
inflammatory bowel disease | (12/98) | |||
and psoriasis | ||||
Myriad Genetics | Monsanto Co. | Research collaboration; use | $15M | 12-15 month collaboration; Myriad gets |
Inc. | (NYSE:MTC) | of Myriad's protein interac- | $15M total, including up-front payment, | |
tion database ProNet to un- | option payments, license fees and mile- | |||
derstand biochemical path- | stones; Myriad also gets royalties; | |||
ways of major diseases (Pro- | Monsanto gets option to extend research | |||
Net identifies human proteins | program for additional disease targets; | |||
and links them into specific | further details ND (11/98) | |||
pathways); initial focus on 2 | ||||
specific diseases (undisclosed) | ||||
Schering AG | Research collaboration; | $51M | 5-year collaboration; Myriad gets $20M | |
(Germany) | use of Myriad's protein | up-front and option to co-promote all | ||
interaction database ProNet | new therapeutics in North America, in | |||
to understand biochemical | which case Myriad will get 50% of profits; | |||
pathways of major diseases | if Myriad doesn't exercise option, it | |||
(ProNet identifies human | gets "substantial" royalties; Myriad can | |||
proteins and links them | exercise co-promotion option by paying | |||
into specific pathways) | 50% of drug development costs; total | |||
$51M to Myriad also includes license and | ||||
subscription fees and milestones (10/98) | ||||
Neoprobe Corp. | CIS-US Inc. (sub- | Letter of intent to license | ND | CIS will be exclusive supplier of radio- |
sidiary of CIS- | CIS' I-125-MIBG drug | labeled drug to Neoprobe in its licensed | ||
Biointernational; | for use in intraoperative | territory (not identified) (12/98) | ||
France) | detection of neuroblastoma | |||
NetGenics Inc.* | American Home | Collaboration; use of | ND | 4-year agreement; NetGenics will pro- |
Products Corp. | NetGenics' Synergy | vide enterprise-wide infrastructure for | ||
(NYSE:AHP) | application framework and | drug discovery within American Home's | ||
software engineering | divisions; financial terms ND (10/98) | |||
services to integrate and | ||||
enhance American Home's | ||||
bioinformatics, genomics | ||||
and drug discovery programs | ||||
Neurocrine | Medtronic Inc. | Clinical collaboration; evalu- | ND | Companies will collaborate to evaluate |
Biosciences Inc. | (NYSE:MDT) | ation of Neurocrine's drug | combined system in the clinic; further | |
NBI-3001 (interleukin-4 Pseu- | details ND (11/98) | |||
` | domonas exotoxin fusion | |||
protein), delivered directly | ||||
into brain via Medtronics' | ||||
implantable infusion pump | ||||
(SynchroMed) for treating | ||||
malignant brain tumors | ||||
Octagen Corp.* | Beaufour Ipsen | Collaboration; use of | ND | Beaufour made equity investment in |
(France) | Octagen's 2nd-generation | (includes | Octagen and will pay up-front fee, R&D | |
genetically engineered | equity) | funding, milestones and royalties; | ||
Factor VIII for therapies | Beaufour gets exclusive worldwide | |||
for hemophilia | license on any products (10/98) | |||
Oravax Inc. (OTC | Pasteur Merieux | Co-development agree- | $23.5M | Pasteur Merieux gets exclusive world- |
Bulletin Board: | Connaught (unit | ment on vaccine for | wide license; Oravax will develop | |
ORVX) | of Rhone-Poulenc | Dengue fever (mosquito- | vaccine through Phase I trials, after | |
Group; NYSE:RP; | born disease caused by | which Pasteur Merieux will take over | ||
France) | any of 4 related viruses); | development, manufacturing, marketing | ||
use of Oravax's Chimeri- | and sales; OraVax got initial fee of $1M | |||
Vax platform technology | and also gets R & D funds ($6M over | |||
that uses yellow fever 17D | next 12 months), milestones ($16.5M) | |||
vaccine virus as vector for | and royalties; Pasteur Merieux has | |||
genes of related viruses | option to negotiate separate agreement | |||
to license Oravax's Japanese encephali- | ||||
tis vaccine worldwide except Korea; in | ||||
exchange, Pasteur Merieux will fund | ||||
development and Phase I clinical trial | ||||
of encephalitis vaccine (12/98) | ||||
Oxford Asymmetry | The Ares-Serono | Combinatorial chemistry | $4.6M | 2-year agreement; Oxford will supply |
International plc | Group | collaboration; use of | libraries for use in Ares-Serono's | |
(LSE:OAI; U.K.) | (Switzerland) | Oxford's chemical com- | Geneva and Boston labs; Oxford gets | |
pound libraries in Ares- | $4.6M over 2 years and additional | |||
Serono's drug lead | payments for each product that is | |||
discovery programs | commercialized (prices converted at | |||
a rate of £0.59/US$1) (10/98) | ||||
Oxford BioMedica | RPR Gencell | Collaboration and license | $17.9M | RPR Gencell gets exclusive worldwide |
plc (AIM:OXB; U.K.) | (division of | agreement on Oxford's | (equity; | license; Oxford gets at least $1M in |
Rhone-Poulenc | Hypoxia Response | % ND) | research funds over 1st 2 years; RPR | |
Rorer Inc.; sub- | Element (control element | will buy 1.5M shares at $0.34 each (at | ||
sidiary of Rhone- | that switches genes on/off | 100% premium) for $0.51M; RPR will | ||
Poulenc SA; | in response to oxygen | buy more stock ($16.4M total at 10% | ||
NYSE:RP; France) | levels) for use in Gencell's | premium) to pay for milestones; Ox- | ||
cardiovascular gene | ford will develop screens for small mol- | |||
therapy products | ecule therapeutics; Oxford also gets | |||
royalties (prices converted at a rate of | ||||
£0.59/US$1) (12/98) | ||||
PathoGenesis | Bristol-Myers | License agreement on | $4M | Pathogenesis gets exclusive worldwide |
Corp. | Squibb Co. | Bristol-Myers' antibiotic | license in exchange for initial payment | |
(NYSE:BMY) | drug candidate (PA-1806; | of $4M; it will also pay milestones and | ||
monobactam) for treating | royalties to Bristol-Myers (10/98) | |||
various bacteria that cause | ||||
chronic lung infections; to | ||||
be delivered via inhalation | ||||
Pangea Systems | Bristol-Myers | License agreement on | ND | ND (9/98) |
Inc.* | Squibb Co. | Pangea's computational | ||
(NYSE:BMY) | algorithms for clustering | |||
and alignment of expressed | ||||
sequence tags within large | ||||
databases; for use in | ||||
Bristol-Myer's genomics | ||||
research | ||||
Monsanto Co. | License agreement on | ND | ND (11/98) | |
(NYSE:MTC) | Pangea's computational | |||
algorithms for clustering | ||||
and alignment of expressed | ||||
sequence tags within large | ||||
databases; for use in | ||||
Monsanto's life sciences | ||||
genomics research (agri- | ||||
cultural and pharmaceutical) | ||||
Pharmacopeia Inc. | Schering AG | Multi-target screening | $64M | Chemical optimization of active com- |
(Germany) | agreement; use of Pharma- | pounds identified via high-throughput | ||
copeia's multi-million | screening may be performed by either | |||
small compound library to | company; Pharmacopeia gets $64M in | |||
screen multiple targets | R & D payments and milestones, plus | |||
chosen by Schering | royalties (10/98) | |||
Schering-Plough | Research collaboration; | $60M | This is 2nd new collaboration between | |
Corp. (NYSE:SGP) | use of Pharmacopeia's | the parties; Pharmacopeia gets $60M | ||
combinatorial libraries | in research funds over 5 years; it also | |||
for discovering and | gets milestones and royalties; Pharma- | |||
optimizing lead drug | copeia will create combinatorial librar- | |||
candidates against targets | ies for use by Schering-Plough; Pharma- | |||
chosen by Schering-Plough | copeia will also design an entire discov- | |||
ery program around Schering-Plough's | ||||
targets; further details ND (11/98) | ||||
PPD Discovery | Rhone-Poulenc | Functional genomics | $30M | 4-year agreement; Rhone-Poulenc will |
(subsidiary of Phar- | Rorer Inc. (sub- | collaboration; use of PPD's | fund R & D; Rhone-Poulenc gets world- | |
maceutical Product | sidiary of Rhone- | GSX System (isolates fun- | wide rights to therapeutics developed | |
Development Inc.) | Poulenc SA; | ctional inhibitors, or gene- | from gene targets; PPD gets worldwide | |
NYSE:RP; France) | tic suppressor elements, of | rights to diagnostic uses, including | ||
any gene) to identify human | pharmacogenomics; PPD also gets | |||
gene targets in oncology, | rights to develop therapeutics for targets | |||
inflammation, cardiovascular | not chosen by Rhone-Poulenc, on which | |||
diseases and central nervous | Rhone-Poulenc has 1st option on | |||
system disorders | license; Rhone-Poulenc gets non-exclu- | |||
sive license to GSX technology; PPD | ||||
and Rhone-Poulenc will pay each other | ||||
milestones and royalties on each other's | ||||
products; PPD gets $20-$30M if targets | ||||
in 2 of 4 therapeutic areas are identified | ||||
and validated (12/98) | ||||
Proteome Sciences | Rhone-Poulenc | Research collaboration; | ND | 2-year agreement; Rhone-Poulenc |
plc (AIM:PRM; U.K.) | Rorer Inc. (sub- | use of proteomics to | Rorer will fund research and retains all | |
sidiary of Rhone- | identify differentially | rights to therapeutic uses for heart | ||
Poulenc SA; | regulated proteins in failing | disease and heart failure; Proteome | ||
NYSE:RP; France) | myocardium (cardiovascular | retains all rights to diagnostics; Proto- | ||
disease) | ome and Harefield Hospital (U.K.) get | |||
royalties for therapeutics (9/98) | ||||
Sangamo Bio- | Bayer Corp. | Research collaboration; | ND | Bayer gets specific GeneTools to evalu- |
Sciences Inc.* | (unit of Bayer AG; | use of Sangamo's Universal | ate; companies may enter into broader | |
Germany) | GeneTools (rationally | agreement; details ND (12/98) | ||
designed zinc finger DNA | ||||
recognition proteins that | ||||
selectively recognize and | ||||
regulate any target gene or | ||||
DNA sequence) to identify | ||||
and validate gene targets | ||||
for drug discovery | ||||
Pfizer Inc. | Research collaboration; | ND | Pfizer will provide funding in exchange | |
(NYSE:PFE) | use of Sangamo's Universal | for use of Sangamo's technology; | ||
GeneTools (rationally | financial terms ND (9/98) | |||
designed zinc finger DNA | ||||
recognition proteins that | ||||
selectively recognize and | ||||
regulate any target gene or | ||||
DNA sequence) to validate | ||||
gene targets for drug discovery | ||||
SmithKline | Research collaboration; | ND | ND (10/98) | |
Beecham plc | use of Sangamo's Universal | |||
(NYSE:SBH; U.K.) | GeneTools (rationally | |||
designed zinc finger DNA | ||||
recognition proteins that | ||||
selectively recognize and | ||||
regulate any target gene or | ||||
DNA sequence) in Smith- | ||||
Kline's transgenic mouse | ||||
systems for validating gene | ||||
targets | ||||
Zeneca Pharma- | Research collaboration; | ND | Zeneca will provide funding to San- | |
ceuticals (unit of | use of Sangamo's Universal | gamo in exchange for use of technol- | ||
Zeneca Group | GeneTools (rationally | ogy; further details ND (11/98) | ||
plc; NYSE:ZEN; | designed zinc finger DNA | |||
U.K.) | recognition proteins that | |||
selectively recognize and | ||||
regulate any target gene or | ||||
DNA sequence) to identify | ||||
and validate gene targets | ||||
for drug discovery | ||||
Sepracor Inc. | Eli Lilly and Co. | License agreement on | $90M | Lilly gets exclusive worldwide license; |
(NYSE:LLY) | Sepracor's single-isomer | Sepracor gets up-front milestone pay- | ||
version of fluoxetine | ment and license fee of $20M total, plus | |||
(active ingredient in | $70M in additional milestones and | |||
Prozac) for treating | royalties; Lilly gets rights for all uses | |||
depression (currently in | and indications; Lilly responsible for | |||
U.S. Phase I trials) | all subsequent product development, | |||
regulatory submissions, manufacturing, | ||||
marketing and sales (12/98) | ||||
SkyePharma plc | Novartis Pharma | Collaboration; use of Skye- | $10.1M | Companies will jointly develop new formu- |
(U.K.) | AG (Switzerland) | Pharma's multi-dose dry | (2% | lation; SkyePharma responsible for finished |
powder inhaler device to | equity) | formulation, including manufacturing; | ||
make new formulation of | Novartis will pay technology access fee, | |||
long-acting bronchodilator | development costs and milestones; Novartis | |||
Foradil (beta-agonist for | also bought $10.1M in equity (8.6M shares | |||
treating asthma) | at $1.174 each; at 13% premium) for 2% stake; | |||
Novartis gets exclusive worldwide rights; | ||||
SkyePharma gets royalties (prices | ||||
converted at rate of £0.59/US$1) (11/98) | ||||
Supratek Pharma | RPR Gencell | Collaboration; use of | ND | RPR Gencell will fund feasibility study |
Inc.* (Canada) | (division of | Supratek's biotransport | of Supratek's system and gets option on | |
Rhone-Poulenc | carrier technology (gene | exclusive license (11/98) | ||
Rorer Inc.; sub- | delivery system) for certain | |||
sidiary of Rhone- | of RPR Gencell's cardio- | |||
Poulenc SA; | vascular projects | |||
NYSE:RP;France) | ||||
Targeted Genetics | Medeva plc | Research collaboration | $54M | Targeted Genetics gets $54M, comprised |
Corp. | (NYSE:MDV; U.K.) | on Targeted Genetics' | (equity; | of $5M license fees, $19M in milestones, |
tgAAV-CF gene therapy | % ND) | $3M in equity investment, $2M loan and | ||
product for treating | $15M research funding over 3 years; it also | |||
cystic fibrosis (uses adeno- | has option under certain conditions to get | |||
associated virus to deliver | another loan of $10M for building manu- | |||
normal CFTR gene) | facturing facility for product; Medeva will | |||
fund clinical and regulatory costs; | ||||
Targeted Genetics will manage U.S. clinical | ||||
trials through Phase I and may manage | ||||
Phase IIs; Medeva will manage all | ||||
other trials; Medeva will buy product | ||||
from Targeted Genetics under long-term | ||||
supply agreement (11/98) | ||||
TerraGen Diversity | Schering-Plough | Collaboration; use of | ND | TerraGen will generate and screen |
Inc.* (Canada) | Research Institute | TerraGen's combinatorial | libraries of traditionally inaccessible | |
(unit of Schering- | biosynthesis technology | microbial compounds; TerraGen gets | ||
Plough Corp.; | to discover anti-infective | annual R & D funds, milestones and | ||
NYSE:SGP) | compounds derived from | royalties; Schering-Plough responsible | ||
unculturable, environ- | for product development; TerraGen | |||
mental microorganisms | retains rights to its libraries; parties | |||
will jointly patent chemical structures | ||||
of lead compounds (12/98) | ||||
Tularik Inc.* | Knoll AG | Collaboration on drugs | ND | 3-year agreement; Tularik gets R&D |
(Germany) | that act on regulatory | funds, milestones and royalties; Knoll | ||
targets in energy metabol- | responsible for all product development | |||
ism pathways, for treating | (preclinical through regulatory clear- | |||
obesity | ance); Knoll gets worldwide marketing | |||
rights, except in Asia; Knoll has option | ||||
of expanding collaboration to include | ||||
additional targets in obesity (12/98) | ||||
Trega Biosciences | Parke-Davis | Research collaboration | ND | This new agreement supercedes the 5/97 |
Inc. | (division of | on Trega's Chem.Folio | agreement between the companies; Parke- | |
Warner-Lambert | (combinatorial chemistry | Davis will buy $1.5M of Trega's combina- | ||
Co.; NYSE:WLA) | libraries) for use in Parke- | torial libraries on nonexclusive basis; as | ||
Davis' drug discovery | a result, it will not buy Trega stock (per the | |||
programs | 1997 agreement); further details ND (12/98) | |||
Visible Genetics | Organon Teknika | License agreement on | ND | Visible Genetics gets right to sell |
Inc. (Canada) | (subsidiary of | Organon's Boom tech- | nucleic acid extraction kits based on | |
Akzo Nobel NV; | nology (method for | Boom technology (10/98) | ||
the Netherlands) | extracting RNA and DNA | |||
from plasma and RNA | ||||
from other bodily fluids) | ||||
NOTES: | ||||
# This chart contains information on new agreements, covering the time between 9/23/98 and 12/24/98. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements will appear in the 1/11/99 issue of BioWorld Financial Watch. The chart above also does not include any collaborations that involve agricultural product development (which are covered periodically in this publication). | ||||
A chart covering modified agreements and terminated agreements between big pharma and biotech companies for the same time period (9/23/98-12/24/98) will also appear in the 1/1/99 issue of BioWorld Financial Watch. | ||||
AIM = Alternative Investment Market (U.K.); LSE = London Stock Exchange; ND = Not disclosed, reported and/or available | ||||
* Private companies are indicated with an asterisk. | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock report For Public Biotechnology Companies on pp. 17-18. |